Clinical Trial Update: Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial (NICARAGUA, NCT03425201) evaluating Niraparib in combination with Cabozantinib in advanced urothelial cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Cancer

Drugs mentioned

• Cabometyx (cabozantinib)
• Zejula (Niraparib)

Snippet

Sponsor: Fundacion CRIS de Investigación para Vencer el Cáncer | Conditions: Urothelial Cancer | Phase 1, Phase 2 | Status: COMPLETED